Recovery of reward function in nicotine use disorder using a combination of robotics, electrophysiology, and TMS

Ended Cooperative Agreement Awarded Last action

Award ID
UG3DA054787
Recipient
Awarding agency
Obligated
$1,486,648

Award facts

Assistance listing
93.279 Drug Use and Addiction Research Programs
Completion date
Originally
Place of performance
New Jersey, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Substance use disorders (suds) are associated with reward-related abnormalities of the anterior midcingulate cortex (MCC), a brain region strongly implicated in goal-directed decision-making. Our recent findings show the reward positivity, an electrophysiological signal believed to index sensitivity of the MCC to rewards, to be abnormal in suds: people who abuse substances produce a blunted reward positivity to monetary rewards, but following an overnight period of drug abstinence, the size of the reward positivity is enhanced by drug-related rewards. This maladaptive process is thought to bias the MCC action-selection mechanism to favor behaviors that ultimately converge on drug use. Importantly, we provided compelling evidence that an FDA approved treatment for depression, 10-HZ transcranial magnetic stimulation (TMS) to the prefrontal cortex, can recover the reward function of the MCC in problematic substance users, and further, reverse the magnitude of the reward bias between monetary and drug-related rewards in abstained smokers. These important findings suggest that (i) the reward positivity is a highly sensitive biomarker of SUD severity and treatment efficacy and (II) modulating MCC with TMS may correct the aberrant reward processes that sustain suds. However, given the limitations and variability of conventional TMS methods used to target the MCC, the optimal TMS protocol for MCC modulation is currently unknown. We therefore propose to use a cutting-edge technology called robot-assisted image-guided TMS (RI-TMS) to identify the optimal TMS protocol aimed to restore the reward function of the MCC in suds with the highest level of precision. In the UG3 phase, we will establish the optimal RI-TMS parameters needed to maximize excitatory effects on reward-related MCC electrophysiology in dependent smokers and healthy controls. In study 1, we will utilize powerful quantitative neuroimaging methods to construct stimulation targets based on prefrontal structure, function, and connectivity with MCC, and test the targets efficacy to modulate the reward positivity, decision-making performance, and craving scores in abstained smokers (aim 1). In aim 2, we will evaluate the efficacy of various pulse protocols to enhance and suppress the reward positivity to monetary and cigarette rewards, respectively, in abstained smokers. The targeting protocol achieving our go criteria and with the largest effect size across these aims will advance to the UH3 phase. In aim 3, we will apply our candidate RI-TMS protocol to enhance the reward positivity to monetary rewards and suppress the reward positivity to drug-related rewards in abstinent smokers. We will also assess the protocols impact on decision-making and craving scores. In aim 4, we will assess the long-term effects of the RI-TMS across multiple RI-TMS sessions on reward positivity, decision-making, and smoking behavior (craving, abstinence, and cigarette valuation). Our long-term goal is to provide treatment programs with a more relevant neurocognitive treatment option, which may increase substance users' success in treatment, maintaining abstinence, as well as achieving broader life goals.

Transactions

Action Obligated Date
Amendment $0
Amendment $0
Amendment $0
Amendment $370,619
Amendment $370,619
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $372,705
Original award $372,705
Show all 15

Subawards

Subrecipient Amount Awarded
Stichting Katholieke Universiteit Brabant Recovery of reward function in nicotine use disorder using a combination of robotics, electrophysiology, and TMS $12,084

Quick answers

Who received award UG3DA054787?

UG3DA054787 was awarded to Rutgers, The State University by National Institute on Drug Abuse (National Institutes of Health) on September 30, 2022.

How much is award UG3DA054787 worth?

$1,486,648 has been obligated on UG3DA054787.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login